In January, the U.S. Food and Drug Administration (FDA) issued its first guidance on the use of artificial intelligence (AI)[1] models in drug development and in regulatory submissions titled, ...
Michael Abrams of Numerof & Associates explains the need for the U.S. Food and Drug Administration to move faster on healthcare artificial intelligence governance, and why its drug development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results